VCM
WST icon

Virtue Capital Management’s West Pharmaceutical WST Stock Holding History

Virtue Capital Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278K Buy
+773
New +$236K 0.04% 290
2026
Q1 		– Sell
-1,200
Closed -$332K – 365
2025
Q4 		$332K Sell
1,200
-2,432
-67% -$665K 0.05% 224
2025
Q3 		$217K Buy
3,632
+2,126
+141% +$517K 0.03% 280
2025
Q2 		$330K Sell
1,506
-178
-11% -$38.1K 0.06% 186
2025
Q1 		$377K Buy
1,684
+453
+37% +$125K 0.04% 312
2024
Q4 		$403K Buy
1,231
+164
+15% +$51.6K 0.08% 172
2024
Q3 		$320K Buy
1,067
+242
+29% +$74.1K 0.06% 192
2024
Q2 		$261K Buy
825
+61
+8% +$21.6K 0.04% 308
2024
Q1 		$292K Buy
764
+2
+0.3% +$740 0.05% 296
2023
Q4 		$258K Sell
762
-1,559
-67% -$552K 0.05% 307
2023
Q3 		$875K Hold
2,321
– – 0.15% 126
2023
Q2 		$875K Sell
2,321
-330
-12% -$118K 0.15% 126
2023
Q1 		$947K Buy
2,651
+1,674
+171% +$489K 0.16% 112
2022
Q4 		$230K Buy
+977
New +$232K 0.04% 337
2022
Q2 		– Sell
-4,194
Closed -$1.72M – 415
2022
Q1 		$1.72M Sell
4,194
-1,228
-23% -$481K 0.27% 82
2021
Q4 		$2.54M Buy
5,422
+658
+14% +$283K 0.38% 56
2021
Q3 		$2.02M Buy
4,764
+30
+0.6% +$12.6K 0.36% 59
2021
Q2 		$1.7M Sell
4,734
-492
-9% -$163K 0.34% 66
2021
Q1 		$1.47M Buy
5,226
+115
+2% +$32.9K 0.35% 68
2020
Q4 		$1.45M Sell
5,111
-386
-7% -$108K 0.36% 77
2020
Q3 		$1.51M Sell
5,497
-536
-9% -$142K 0.37% 77
2020
Q2 		$1.37M Buy
+6,033
New +$1.19M 0.32% 92
2020
Q1 		– Sell
-4,044
Closed -$608K – 215
2019
Q4 		$608K Buy
4,044
+1,220
+43% +$178K 0.18% 113
2019
Q3 		$400K Buy
2,824
+1,126
+66% +$155K 0.13% 162
2019
Q2 		$213K Buy
+1,698
New +$200K 0.08% 201

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Virtue Capital Management's WST Position: Q2 2026 in Review

Virtue Capital Management opened a new position in West Pharmaceutical (WST) in Q2 2026: 773 shares worth $278K. The stake represents 0.04% of the portfolio and ranks #290 among its holdings. This is a return to the name: Virtue Capital Management previously reported a position in WST as recently as Q4 2025.

Virtue Capital Management first reported a position in WST in Q2 2019 and has held it in 25 quarters since. The position peaked at $2.54M in Q4 2021. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Virtue Capital Management held 773 shares of West Pharmaceutical worth $278K as of Q2 2026.
  • West Pharmaceutical was a new Virtue Capital Management position in Q2 2026.
  • West Pharmaceutical made up 0.04% of Virtue Capital Management's portfolio in Q2 2026, its #290 holding.
  • Virtue Capital Management first reported a position in West Pharmaceutical in Q2 2019 and has held it in 25 quarters since.
  • Virtue Capital Management's West Pharmaceutical position peaked at $2.54M in Q4 2021.
  • 831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Virtue Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.